济南小便马眼刺{痛}(济南男性泌尿科检查) (今日更新中)

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

SAN FRANCISCO, June 28 (Xinhua) -- Google has launched a new site wdyl.com, a search service standing for "what do you love" and integrating a variety of Google's search products on one page.According to a report by technology blog TechCrunch, wdyl.com was quietly rolled out several days ago and the formal launch was set for Monday, but engineering issues have been holding it back until early Tuesday morning.The site can return users a single page of relevant results across a variety of Google's search services for whatever query is typed into the search box, whose search button is even a heart.For example, after typing in "pasta," several columns appear on the search results page, allowing users to see images of pasta, watch videos of pasta, or browse latest news about pasta.Other search results include pasta-related maps, books, blogs, patents, translation, popularity on the web and etc.

WARSAW, June 2 (Xinhua) -- A possible second E. coli infection patient has been hospitalized in Szczecin, northwestern Poland, Health Minister Ewa Kopacz said Thursday.The man, who recently returned to Poland from Germany, has been diagnosed with exudative diarrhea and is currently being tested for E. coli bacteria.Poland's first E. coli case, a 29-year-old woman permanently residing in Germany and diagnosed with the bacteria over a week ago, is currently in the same hospital.Kopacz said sanitary teams were running E. coli checks countrywide, especially on marketplaces and in warehouses.The E. coli epidemic originated in Germany, where it has taken 17 lives. One death has so far occurred in Sweden, bringing the total death toll to 18.

SAN FRANCISCO, June 14 (Xinhua) -- Apple updated its online store on Tuesday to begin offering unlocked models of iPhone 4 in the United States for the first time."The unlocked iPhone 4 requires an active micro-SIM card that you obtain from a supported GSM wireless carrier," said Apple in the product description. The iPhone requires a smaller version of the standard SIM (Subscriber Identity Module) card.Started at 649 U.S. dollars for the 16 GB version, the unlocked model is a GSM phone, which means, in the United States, the phone runs on networks of T-Mobile or AT&T, although it can only send data over T-Mobile's old EDGE network, not its 3G network and the faster HSPA+ network.Verizon and Sprint, the other two major U.S. wireless carriers, both use CDMA networks that do not use SIM cards.The iPhone 4 has been sold unlocked in other countries. For frequent international travelers, an unlocked iPhone means they just need to pop in a micro-SIM card for whichever country they are going, avoiding provider's high international fees.According to Apple, iPhone sales grew 113 percent year over year in the second quarter of its fiscal 2011, reaching a record high of 18.65 million units.

SYDNEY, Sept. 5 (Xinhua) -- Australian scientists believe " brown fat," a wondrous tissue that burns energy to generate heat, could help people fight obesity, local media reported on Monday.A research team from Sydney's Garvan Institute of Medical Research (GIMR) has worked out how to grow brown fat from stem cells biopsied from adults, raising hopes that one day brown fat could be transplanted in obese people to speed up calories they burn, the Australian Associated Press (AAP) reported.Garvan endocrinologist Paul Lee, who led the research, is optimistic about targeting brown fat as an obesity intervention, commenting "it's a highly metabolically active form of fat, and very exciting that we may be able to stimulate its growth in people."People are born with supplies of brown fat around their neckline to keep them warm as infants, according to scientists at GIMR.Scientists now know that brown fat is present in most, if not all, adults mainly just behind the collarbone.Studies have found that adults with brown fat are slimmer than those without."Although this is early work, it is a proof of concept study showing that the growth of brown fat cells is possible, using precursor cells taken from adult humans, under appropriate stimulation," Lee said."Regardless of whether or not someone has lots of or little brown fat, the precursor cells are universally present. Under the appropriate growth factor and hormonal stimulation, the cells all grow and differentiate into mature brown fat cells."However, Lee warned more work was needed.Lee said even if brown fat was transplanted into obese people or drugs developed to stimulate the growth of brown fat, exercise and a healthy diet would still be crucial to aiding weight loss."So I don't think this is a solution to obesity because there are so many other factors (involved in obesity)," he said."Despite how efficient brown fat is at burning energy, we would only need a few doughnuts to diminish or negate its benefits."Lee said it would be years before tests could be carried out on brown fat transplants.In the meantime, he is expanding his study to test different ways to grow brown fat.His study, to be printed in the October issue of Endocrinology, has been published in the online edition of the journal.

来源：资阳报